EANO Meeting - Friday, September 22, 2023
Note that the programme is subject to change and will be continuously updated.
All times below refer to Central European Summer Time (CEST).
08:00-09:00 hrs
Chairs: tba
ME01.1 Molecular evolution of brain metastases and its clinical implications
Manuel Valiente, Spain
ME01.2 Systemic treatment as first option: impact of target agents and immunotherapy (clinical case)
Dieta Brandsma, Netherlands
ME01.3 Management of brain metastases at further progression
Emilie Le Rhun, Switzerland
ME01.4 Surgery for brain metastases: extent of resection and functional preservation
Einar Vik-Mo, Norway
Chair: tba
ME02.1 Ultrasound mediated drug delivery in brain
Alexandre Carpentier, France
ME02.2 Pre-clinical assessment of FUS BBB opening
Antonis Pouliopoulos, United Kingdom
ME02.3 FUS in immunotherapy of glioma
Natasha Sheybani, United States
ME02.4 Ultrasound in Neurosurgery: from imaging to therapy
Francesco Prada, Italy
Chairs: tba
ME03.1 Re-irradiation for primary brain tumours: pros and cons versus surgery
Louise Murray, United Kingdom
ME03.2 Data collection and models for outcome prediction in brain re-irradiation
Maximillian Niyazi, Germany
ME03.3 Application of FLASH radiotherapy for re-irradiation
Pierre Montay-Gruel, Belgium
09:00-09:15 hrs | BREAK
09:15-10:45 hrs
Chairs: tba
OS02.1 Revisiting strategies to deliver equitable care to underserved populations in neuro-oncology
Shawn Hervey-Jumper, United States
OS02.2 Barriers to accrual and enrollment in brain tumor trials – the patient and caregiver perspective
Kathy Oliver, United Kingdom
OS02.3 Improving recruitment for TYA patients
Dan Stark, United Kingdom
JS02.1 Overview EORTC Brain Tumor Group Study Activities
Matthias Preusser, Austria
Chair EORTC Brain Tumor Group
JS02.2 Neuro-Oncology Journal
Susan Chang, United States
Editor-in-Chief Neuro-Oncology Journal
JS02.3 Neuro-Oncology Advances Journal
Gelareh Zadeh, Canada
Editor-in-Chief Neuro-Oncology Advances Journal
JS02.4 Neuro-Oncology Practice Journal
Martin Taphoorn, Netherlands
Editor-in-Chief Neuro-Oncology Practice Journal
Chairs: tba
OS03.1 AI in histology classification
Moritz Gerstung, Germany
OS03.2 AI in cytology evaluation
Leonille Schweizer, Germany
OS03.3 AI in neuroradiology routine
Julia Furtner-Srajer, Austria
OS03.4 AI in sequencing and variant classification
Matthew Loose, United Kingdom
10:45-11:15 hrs | COFFEE BREAK
11:15-13:00 hrs
Susan Short, United Kingdom
President EANO
Martin van den Bent, Netherlands
President EANO Meeting 2023
Manuel Valiente, Spain
Chair EANO Scientific Committee
Chairs: tba
PL01.1 Brain immunity: basic biology and strategies to challenge CNS disorders
Jonathan Kipnis, United States
PL01.2 Vaccine strategies to challenge brain tumors
Michael Platten, Germany
PL01.3 Cell-based strategies to challenge brain tumors
Dinorah Friedmann-Morvinski, Israel
13:00-14:30 hrs | LUNCH BREAK
13:15-14:15 hrs
Chairs: tba
Group A
WS01.1 How to peer-review: The Editor's perspective in translational science
Feline Dijkgraaf, Netherlands
WS01.2 How to peer-review: The reviewer's perspective translational science
Kenneth Aldape, United States
Group B
WS01.3 How to peer-review: The Editor's perspective in clinical science
Susan Chang, United States
WS01.4 How to peer-review: The reviewer's perspective in clinical science
Matthias Preusser, Austria
Group C
WS01.5 How to peer-review: The Editor's perspective in basic science
Elizabeth McKenna, United States
WS01.6 How to peer-review: The reviewer's perspective in basic science
Dieter Henrik Heiland, Germany
14:30-16:00 hrs
Chairs: tba
KS01.1 A perspective of ADC in Oncology
Nancy Lin, United States
KS01.2 ADC in primary brain tumors
Andrew Lassman, United States
KS01.3 Emerging classes of engineered antibody therapeutic candidates
Daniel Christ, Australia
KS01.4 Improving BBB/BTB penetration of antibody-based therapies
Costas Arvanitis, United States
Chairs: tba
OS04.1 Pro-Cons adjuvant treatment: PCV vs TMZ
Anna Berghoff, Austria
OS04.2 Radiological follow up
Francesco Sanvito, United States
OS04.3 Long term cognitive effects
Florien Boele, United Kingdom
Chairs: tbc
OS05.1 A symptom tracking and reporting instrument mobile application for central nervous system cancer patients
Terri Armstrong, United States
OS05.2 Developing an APP for patient with PMBT
Petra Hoogendoorn, Netherlands
OS05.3 A regulatory perspective
Joaquín Cayón, Spain
OS05.4 Clinical evidences of the benefits of eHealth
Frank Giordano, Germany
16:00-16:15 hrs | BREAK
16:15-17:45 hrs
Chairs: tba
KS02.1 Systemic treatment: IDH inhibitors and PARP inhibitors
Maria Vieito, Spain
KS02.2 Surgery in IDH mutant gliomas
Louise Carstam, Sweden
KS02.3 Proton versus photon radiotherapy
Danielle Eekers, Netherlands
KS02.4 Targeting pyrimidine nucleotide metabolism in IDH-mutant glioma
Samuel McBrayer, United States
Chairs: tba
PC01.1 Increased granularity of molecular subtyping - con arguments
Kathreena Kurian, United Kingdom
PC01.2 Increased granularity of molecular subtyping - pro arguments
Abigail Suwala, Germany
PC01.3 Routine application of comprehensive molecular testing - con arguments
Pascale Varlet, France
PC01.4 Routine application of comprehensive molecular testing - pro arguments
Pieter Wesseling, Netherlands
Chairs: tba
JS03.1 Models and trials for scoring brain impact of tumors and their treatments
Donald Mabbott, Canada
JS03.2 Brain impact of targeted therapies and immunotherapies
Sanne Schagen, Netherlands
JS03.3 Long term epilepsy associated tumors
Johan Pallud, France
JS03.4 Basic mechanism networks-seizures in glioma
Gilles Huberfeld, France
